Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$25.79 USD
+1.16 (4.71%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $25.79 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
Intellia Therapeutics, Inc. [NTLA]
Reports for Purchase
Showing records 221 - 240 ( 287 total )
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Impact on Coverage Universe: Week of April 13 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Impact on Coverage Universe: Week of March 30 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q19: The First Product to Enter into the Clinic in 2020
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
One Step Forward Two Steps Back, Downgrading to Neutral
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
In Vivo and Ex Vivo Therapies Show Encouraging Preclinical Data
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ATTR and AML Plans Are On Track With Cash Runway Through 2021
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Intellia Is Now Entitled to the Majority Share of Worldwide ATTR Sales
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASH 2019: Hangover: Covered Companies Roundup
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Naming Next Dev Candidate by YE, Lead Program in Clinic Mid-2020
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q19: Modular Therapy May Unlock Opportunities. ''2001 IND Filing On Track
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T